WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 02/07/24

2024-02-07 11:28:54 ET More on I-Mab Biopharma Seeking Alpha’s Quant Rating on I-Mab Biopharma Historical earnings data for I-Mab Biopharma Financial information for I-Mab Biopharma Read the full article on Seeking Alpha For further details see...

2024-02-01 03:00:00 ET Summary Beijing is rolling out a host of measures to boost economic growth and support sagging stock markets. The policies helped Hong Kong’s Hang Seng jump 4.2% last week, breaking a January losing streak. Under a new policy, market valuation will be...

2024-01-18 00:00:00 ET Summary Emerging markets equities saw positive performance in 4Q 2023, driven by valuation re-rating and currency strength. Taiwan Region, India and South Korea boosted benchmark returns, while China underperformed. Brazil remains the Strategy’s l...

2024-01-08 06:37:00 ET More on Wuxi Biologics ADR WuXi Bio Prescribes Share Buyback To Relieve Revenue Pain WuXi Biologics: Holiday Fire Sale For Leading CRDMO Historical earnings data for Wuxi Biologics ADR Financial information for Wuxi Biologics ADR ...

2023-12-13 20:30:00 ET Summary After its shares plunged more than 30% in a week, WuXi Bio announced a buyback of 10% of its shares, saying the battered price did not reflect the company’s value or business prospects. The company blamed the weaker revenue outlook on a financ...

2023-12-10 02:15:00 ET Summary Shanghai Abbisko Therapeutics has sold greater China commercialization rights for pimicotinib to Germany's Merck in a $605 million deal. Xtalpi, a China-US AI drug discovery company, has filed for a Hong Kong IPO after raising $780 million in venture...

2023-12-06 02:05:56 ET Summary WuXi Biologics is a contract-based drug developer in China, but recent share price performance has lagged. The company is expecting a major miss in revenues for FY 2023 due mostly to over-optimism, causing a 30% decline in share price. Despite th...

2023-11-29 17:57:54 ET Summary Ajinomoto is diversifying its revenue segments, particularly in the biopharma and semiconductor industries, for organic growth opportunities. The company has a leading market position, high R&D investment, and above-peer margins in the consumer s...

2023-11-26 02:40:00 ET Summary BeiGene acquires global rights to a preclinical CDK2 inhibitor from Ensem Therapeutics in a $1.3 billion agreement. Shanghai Usynova Biopharma out-licenses global rights for its KRASG12D inhibitor to AstraZeneca in a deal worth up to $419 million. ...

WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale PR Newswire By leveraging WuXiUP TM , WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing ...